Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

United Therapeutics (UTHR) Interest Expenses (2016 - 2026)

United Therapeutics' Interest Expenses history spans 17 years, with the latest figure at $3.1 million for Q4 2025.

  • On a quarterly basis, Interest Expenses fell 60.76% to $3.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $19.5 million, a 54.55% decrease, with the full-year FY2025 number at $19.5 million, down 54.55% from a year prior.
  • Interest Expenses hit $3.1 million in Q4 2025 for United Therapeutics, up from $3.0 million in the prior quarter.
  • Over the last five years, Interest Expenses for UTHR hit a ceiling of $15.6 million in Q3 2023 and a floor of $3.0 million in Q3 2025.
  • Historically, Interest Expenses has averaged $8.6 million across 5 years, with a median of $7.6 million in 2024.
  • Biggest five-year swings in Interest Expenses: soared 193.62% in 2023 and later crashed 70.3% in 2025.
  • Tracing UTHR's Interest Expenses over 5 years: stood at $4.7 million in 2021, then skyrocketed by 161.7% to $12.3 million in 2022, then rose by 22.76% to $15.1 million in 2023, then tumbled by 47.68% to $7.9 million in 2024, then tumbled by 60.76% to $3.1 million in 2025.
  • Business Quant data shows Interest Expenses for UTHR at $3.1 million in Q4 2025, $3.0 million in Q3 2025, and $7.3 million in Q2 2025.